Cypherpunk Technologies(DE:5MC)
€1.550.00 (0.00%)
DE:5MC
Cypherpunk Technologies stock drug pipeline
€1.55
At close:0.00 (0.00%)
Cypherpunk Technologies (5MC) Drug Pipeline
1 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bevacizumab, Folfiri, Folfox, Dkn-01 | Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Colo-Rectal Cancer | Phase II | Completed | Phase 2 Study of DKN-01 in Colorectal Cancer | Jul 21, 2022 | ― |
| Fluorouracil, Oxaliplatin, Dkn-01 300Mg, Dkn-01 600Mg, Dkn-01 400Mg, Tislelizumab 200Mg, Tislelizumab 400Mg, Capecitabine 1000Mg/ M2 Twice Daily (Bid), Leucovorin Calcium | Gastroesophageal Cancer, Gastric Cancer, Gastric Adenocarcinoma | Phase II | Terminated | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer | Apr 23, 2020 | ― |
| Paclitaxel, 300Mg Dkn-01, 600Mg Dkn-01 | Ovarian Cancer, Endometrial Cancer, Uterine Cancer, Carcinosarcoma | Phase II | Completed | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | Jan 02, 2018 | ― |
| Trx518 Monotherapy, Trx518 With Gemcitabine, Trx518 With Pembrolizumab, Trx518 With Nivolumab | Solid Tumors | Phase I | Completed | Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab | Dec 01, 2015 | ― |
| Gemcitabine, Cisplatin, Dkn-01 | Bile Duct Cancer, Cholangiocarcinoma, Carcinoma Of Intrahepatic And Extra-Hepatic Biliary System, Carcinoma Of Gallbladder | Phase I | Completed | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | Feb 18, 2015 | ― |
| Pembrolizumab, Paclitaxel, Dkn-01 150 Mg, Dkn-01 300 Mg | Gastroesophageal Cancer, Gastric Adenocarcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Esophageal Neoplasms | Phase I | Completed | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | Dec 11, 2013 | ― |
| Standard of Care, Dkn-01 300 Mg, Dkn-01 600 Mg | Multiple Myeloma | Phase I | Completed | A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Oct 18, 2012 | ― |
| Trx518 | Unresectable Stage Iii Or Stage Iv Malignant Melanoma Or Other Solid Tumor Malignancies | Phase I | Completed | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | Nov 09, 2010 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bevacizumab, Folfiri, Folfox, Dkn-01 | Phase II | Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Colo-Rectal Cancer | Completed | Phase 2 Study of DKN-01 in Colorectal Cancer | Jul 21, 2022 | ― |
| Fluorouracil, Oxaliplatin, Dkn-01 300Mg, Dkn-01 600Mg, Dkn-01 400Mg, Tislelizumab 200Mg, Tislelizumab 400Mg, Capecitabine 1000Mg/ M2 Twice Daily (Bid), Leucovorin Calcium | Phase II | Gastroesophageal Cancer, Gastric Cancer, Gastric Adenocarcinoma | Terminated | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer | Apr 23, 2020 | ― |
| Paclitaxel, 300Mg Dkn-01, 600Mg Dkn-01 | Phase II | Ovarian Cancer, Endometrial Cancer, Uterine Cancer, Carcinosarcoma | Completed | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | Jan 02, 2018 | ― |
| Trx518 Monotherapy, Trx518 With Gemcitabine, Trx518 With Pembrolizumab, Trx518 With Nivolumab | Phase I | Solid Tumors | Completed | Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab | Dec 01, 2015 | ― |
| Gemcitabine, Cisplatin, Dkn-01 | Phase I | Bile Duct Cancer, Cholangiocarcinoma, Carcinoma Of Intrahepatic And Extra-Hepatic Biliary System, Carcinoma Of Gallbladder | Completed | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | Feb 18, 2015 | ― |
| Pembrolizumab, Paclitaxel, Dkn-01 150 Mg, Dkn-01 300 Mg | Phase I | Gastroesophageal Cancer, Gastric Adenocarcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Esophageal Neoplasms | Completed | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | Dec 11, 2013 | ― |
| Standard of Care, Dkn-01 300 Mg, Dkn-01 600 Mg | Phase I | Multiple Myeloma | Completed | A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Oct 18, 2012 | ― |
| Trx518 | Phase I | Unresectable Stage Iii Or Stage Iv Malignant Melanoma Or Other Solid Tumor Malignancies | Completed | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | Nov 09, 2010 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cypherpunk Technologies Inc. (DE:5MC) have in its pipeline
Cypherpunk Technologies DE:5MC is currently developing the following drugs: Bevacizumab, Folfiri, Folfox, Dkn-01, Fluorouracil, Oxaliplatin, Dkn-01 300Mg, Dkn-01 600Mg, Dkn-01 400Mg, Tislelizumab 200Mg, Tislelizumab 400Mg, Capecitabine 1000Mg/ M2 Twice Daily (Bid), Leucovorin Calcium, Paclitaxel, 300Mg Dkn-01, 600Mg Dkn-01, Trx518 Monotherapy, Trx518 With Gemcitabine, Trx518 With Pembrolizumab, Trx518 With Nivolumab, Gemcitabine, Cisplatin, Dkn-01, Pembrolizumab, Paclitaxel, Dkn-01 150 Mg, Dkn-01 300 Mg, Standard of Care, Dkn-01 300 Mg, Dkn-01 600 Mg, Trx518. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

